|
DE2245404C3
(de)
|
1972-09-15 |
1978-08-31 |
Robert Bosch Gmbh, 7000 Stuttgart |
Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
|
|
JPS531908B2
(enExample)
|
1973-11-12 |
1978-01-23 |
|
|
|
JPS5746634B2
(enExample)
|
1974-05-10 |
1982-10-04 |
|
|
|
JPS5146628A
(ja)
|
1974-10-17 |
1976-04-21 |
Nippon Denso Co |
Teikoirisupaakupuragu
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5541104A
(en)
|
1991-05-23 |
1996-07-30 |
Ludwig Institute For Cancer Research |
Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
|
|
US5342774A
(en)
|
1991-05-23 |
1994-08-30 |
Ludwig Institute For Cancer Research |
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
|
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
|
CA2143335C
(en)
|
1992-08-31 |
2000-03-14 |
Thierry Boon-Falleur |
Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
|
|
US6222012B1
(en)
|
1992-08-31 |
2001-04-24 |
Ludwig Institute For Cancer Research |
Isolated nonapeptides presented by HLA molecules, and uses thereof
|
|
DE69524264T2
(de)
|
1994-03-01 |
2002-07-18 |
Ludwig Institute For Cancer Research, New York |
Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
|
|
US6291430B1
(en)
|
1997-09-12 |
2001-09-18 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
|
CA2318576C
(en)
|
1997-12-01 |
2009-04-14 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
|
|
DE19818214A1
(de)
|
1998-04-24 |
1999-10-28 |
Bosch Gmbh Robert |
Zündkerze für eine Brennkraftmaschine
|
|
CA2374398C
(en)
|
1999-05-27 |
2011-03-15 |
Ira Pastan |
Immunoconjugates having high binding affinity
|
|
JP4578025B2
(ja)
|
2001-07-06 |
2010-11-10 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
WO2004035607A2
(en)
|
2002-10-17 |
2004-04-29 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
AU2006204459B2
(en)
|
2005-01-05 |
2012-11-01 |
F-Star Therapeutics Limited |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
EP1851244A4
(en)
|
2005-02-15 |
2009-04-15 |
Gtc Biotherapeutics Inc |
ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
|
|
ES2429340T3
(es)
|
2005-03-10 |
2013-11-14 |
Morphotek, Inc. |
Anticuerpos anti-mesotelina
|
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
GB0624500D0
(en)
|
2006-12-07 |
2007-01-17 |
Istituto Superiore Di Sanito |
A novel passive vaccine for candida infections
|
|
JP5602625B2
(ja)
*
|
2007-06-26 |
2014-10-08 |
エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング |
結合物質のディスプレイ
|
|
CN104151429B
(zh)
|
2007-11-26 |
2018-07-10 |
拜耳知识产权有限责任公司 |
抗-间皮素抗体及其用途
|
|
SG186656A1
(en)
|
2007-12-14 |
2013-01-30 |
Bristol Myers Squibb Co |
Binding molecules to the human ox40 receptor
|
|
AU2009234277B2
(en)
|
2008-04-11 |
2014-12-04 |
Aptevo Research And Development Llc |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
KR20110083730A
(ko)
|
2008-11-13 |
2011-07-20 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
Ｃｄ37 면역치료제 병용 요법 및 이의 용도
|
|
WO2010077634A1
(en)
|
2008-12-09 |
2010-07-08 |
Genentech, Inc. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
AU2010230063B2
(en)
|
2009-03-24 |
2015-06-25 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-mesothelin antibodies
|
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
NZ599405A
(en)
|
2009-11-24 |
2014-09-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
EP2407487A1
(en)
|
2010-07-14 |
2012-01-18 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Multispecific modular antibody
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
UA115641C2
(uk)
|
2010-12-20 |
2017-11-27 |
Дженентек, Інк. |
Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
|
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
EP2546268A1
(en)
|
2011-07-13 |
2013-01-16 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Internalising immunoglobulin
|
|
EP2785375B1
(en)
|
2011-11-28 |
2020-07-22 |
Merck Patent GmbH |
Anti-pd-l1 antibodies and uses thereof
|
|
CN104736168B
(zh)
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
JP5276742B1
(ja)
|
2012-08-09 |
2013-08-28 |
日本特殊陶業株式会社 |
点火プラグ
|
|
AU2013324049B2
(en)
|
2012-09-27 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
DK2925350T3
(da)
|
2012-12-03 |
2019-05-13 |
Bristol Myers Squibb Co |
Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
|
|
SI2970464T1
(sl)
|
2013-03-15 |
2020-08-31 |
Glaxosmithkline Intellectual Propety Development Limited |
Anti-LAG-3 vezavni proteini
|
|
AU2014236769B2
(en)
|
2013-03-15 |
2018-09-27 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
GB201317622D0
(en)
|
2013-10-04 |
2013-11-20 |
Star Biotechnology Ltd F |
Cancer biomarkers and uses thereof
|
|
TW201613635A
(en)
|
2014-02-04 |
2016-04-16 |
Pfizer |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
JP5902757B2
(ja)
|
2014-06-24 |
2016-04-13 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
WO2015198312A1
(en)
|
2014-06-24 |
2015-12-30 |
Ccam Therapeutics Ltd. |
Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
KR20170041249A
(ko)
|
2014-08-10 |
2017-04-14 |
페더럴-모굴 이그니션 컴퍼니 |
개선된 시일을 가진 점화 플러그
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
CA2874083C
(en)
|
2014-12-05 |
2024-01-02 |
Universite Laval |
Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
EP3258959A4
(en)
|
2015-02-22 |
2018-10-17 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd137
|
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
Ｆ 星生物科技有限公司 |
Ｈｅｒ２結合劑治療
|
|
CN107636014B
(zh)
|
2015-05-04 |
2021-12-07 |
皮里斯制药有限公司 |
抗癌融合多肽
|
|
RU2017142008A
(ru)
|
2015-05-21 |
2019-06-24 |
Эллигейтор Биосайенс Аб |
Новые полипептиды
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
JP6025921B1
(ja)
|
2015-06-22 |
2016-11-16 |
日本特殊陶業株式会社 |
スパークプラグ
|
|
CN108348573A
(zh)
|
2015-07-15 |
2018-07-31 |
皮里斯制药有限公司 |
Lag-3特异性的新型蛋白
|
|
AR105444A1
(es)
|
2015-07-22 |
2017-10-04 |
Sorrento Therapeutics Inc |
Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
|
|
CN116333138A
(zh)
|
2015-07-30 |
2023-06-27 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
|
EP3331901A1
(en)
|
2015-08-07 |
2018-06-13 |
Pieris Pharmaceuticals GmbH |
Novel fusion polypeptide specific for lag-3 and pd-1
|
|
CN108026169B
(zh)
|
2015-09-22 |
2021-05-28 |
苏州丁孚靶点生物技术有限公司 |
抗人cd137的完全人抗体及其应用
|
|
KR101782487B1
(ko)
|
2015-09-24 |
2017-09-27 |
재단법인 목암생명과학연구소 |
신규 항-메소텔린 항체 및 이를 포함하는 조성물
|
|
KR20180053674A
(ko)
|
2015-10-02 |
2018-05-23 |
에프. 호프만-라 로슈 아게 |
공자극 tnf 수용체에 특이적인 이중특이성 항체
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
GB201519481D0
(en)
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
|
SG10201911035QA
(en)
|
2015-11-18 |
2020-01-30 |
Merck Sharp & Dohme |
Pd1 and/or lag3 binders
|
|
US20190330336A1
(en)
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
|
JP7022993B2
(ja)
|
2016-01-11 |
2022-02-21 |
インヒブルクス インコーポレイテッド |
多価かつ多重特異性の４１ｂｂ結合融合タンパク質
|
|
CN108602371B
(zh)
|
2016-03-18 |
2020-03-24 |
大日本印刷株式会社 |
中间转印介质、中间转印介质与热转印片的组合、以及印刷物的形成方法
|
|
KR102426765B1
(ko)
|
2016-04-22 |
2022-07-29 |
엘리게이터 바이오사이언스 에이비 |
Cd137에 대한 신규한 이중특이성 폴리펩타이드
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
CA3025345A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
|
|
US20190106494A1
(en)
|
2016-06-13 |
2019-04-11 |
Askgene Pharma Inc. |
PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
|
|
US11214620B2
(en)
|
2016-06-20 |
2022-01-04 |
F-Star Therapeutics Limited |
Binding molecules binding PD-L1 and LAG-3
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
CN107523546A
(zh)
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抗体的nk细胞及其用途
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
US11214618B2
(en)
|
2016-06-20 |
2022-01-04 |
F-Star Therapeutics Limited |
LAG-3 binding members
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
CN109715666B
(zh)
|
2016-07-20 |
2023-02-21 |
斯特库比股份有限公司 |
癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
|
|
CN117510643A
(zh)
|
2016-09-23 |
2024-02-06 |
美勒斯公司 |
调节细胞表达的生物活性的结合分子
|
|
GB201616699D0
(en)
|
2016-09-30 |
2016-11-16 |
Mab Designs Ltd |
Antibodies
|
|
GB201619648D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
WO2018115859A1
(en)
*
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
GB201700345D0
(en)
|
2017-01-09 |
2017-02-22 |
F-Star Beta Ltd |
Conditional agonists of immune responses
|
|
WO2018215835A1
(en)
|
2017-05-26 |
2018-11-29 |
Novimmune Sa |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
|
BR112019018759A2
(pt)
|
2017-05-30 |
2020-05-05 |
Bristol-Myers Squibb Company |
composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico
|
|
JP7290013B2
(ja)
|
2017-08-04 |
2023-06-13 |
ジェンマブ エー／エス |
Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
CN111741976B
(zh)
|
2017-12-19 |
2024-09-17 |
英沃克斯制药有限公司 |
包括pd-l1抗原结合位点的fc结合片段
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
CA3106048A1
(en)
|
2018-07-12 |
2020-01-16 |
F-Star Beta Limited |
Antibody molecules that bind cd137 and ox40
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
CN112423845B
(zh)
|
2018-07-12 |
2024-07-30 |
F-星治疗有限公司 |
结合pd-l1和cd137的抗体分子
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
CA3139003A1
(en)
|
2019-05-14 |
2020-11-19 |
F-Star Therapeutics Limited |
Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
|